ALANTRA Equities

MAKING SCIENCE

2022 points to another strong year

- 2021 results review. As advanced by the company, Q421 sales jumped by >70% to €35m (vs. our €31m on greater organic growth) but adj. EBITDA fell by 6% to €1.1m (vs. our €1.5m estimate) due to higher integration costs and greater negative contribution from the e-commerce Ventis. On a LFL basis, revenues and adj. EBITDA jumped by 53% and 34% respectively in 2021. Net profit for 2021 came out at -€3.2m, below our breakeven estimate, on higher one-offs and PPA amortisation. Net debt stood at €23m, lower than our €29m estimate, mainly thanks to +€5m WC generation (vs. our +€0.2m) and lower M&A investments.
- Busy M&A activity in 2022. Making Science is having a busy start to 2022 on the M&A front: 1) it acquired 70% of Tre Kronor Media, a media agency with presence in the Nordics for €12-13m EV (€1.3m in cash, c.€3m in shares plus earnouts deferred to 2027). It is expected to contribute with €50m sales and €1m EBITDA (100%); 2) it acquired Elliot, a digital marketing agency (€0.1m EV) based in Georgia; and 3) it created Pilot Ignite with Pilot (via JV, owned at 25% by Making Science) a new agency aimed at fostering digital services for Pilot clients in Germany (first operation in the country). Pilot is a member of Local Planet, one of the largest media agency networks owned at 11% by Making Science, and we believe it could become a good client feed and prescriber for the latter.
- 2022 looks good. 1) In the core business, Making Science aims to deliver on synergies of recent M&A, while still growing at double-digit figures organically (vs. our >20% estimate); 2) as for Ventis, Making Science is focused on its turnaround (6X growth in product catalogue, improved UX and SEO) and aims to boost GMV by 45% to €18m (in line); and 3) as for M&A, the group announced back in February its plans to raise capital to fund further inorganic growth. Including 2022 M&A, we estimate adjusted ND at 2.9X EBITDA, leaving limited firepower.
- Changes in estimates. We keep our organic sales growth unchanged at c.20% CAGR 2021-24 but raise our adj. EBITDA by 3% in 2022 and 7% in 2023-24 to reflect the purchase of Tre Kronor Media and slightly higher integration costs. We are fine-tuning adj. EPS, also reflecting higher D&A, minorities & financial costs.
- Our view. Q4 results have been mixed (higher revenue growth with higher-than-expected investments). That said, we believe 2022 points to another strong year both for the core business (industry tailwinds, group's competitive advantages allowing for market share gains, M&A cross-selling opportunities) and for Ventis (delivering on its turnaround, scaling up sales and minimising losses), thus rendering Making Science an attractive stock in our Spanish universe.

Financial Ratios	FY19	FY20	FY21	FY22E	FY23E	FY24E
EBITDA (€m)	2.4	3.7	5.7	10.1	13.1	16.0
Net profit (€m)	0.7	1.5	(3.5)	2.2	4.3	6.5
EPS (€)	0.10	0.22	(0.45)	0.27	0.55	0.82
Adj. EPS (*) (€)	0.28	0.39	0.45	0.70	0.99	1.28
P/E (x)		33.8	n.a.	75.8	38.2	25.3
P/E Adj. (x)		19.2	56.1	29.5	21.0	16.3
EV/EBITDA (x)		14.8	38.4	18.6	13.8	10.7
Debt/EBITDA (x)	0.5	0.7	4.1	2.3	1.3	0.5
P/BV (x)		18.1	18.7	10.9	8.5	6.3
ROE (%)		53.6	n.a.	14.3	22.2	25.0
DPS (€)	0.0	0.0	0.00	0.00	0.00	0.00
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	0.0
(*) Historical multiples base	ed on average sha	are price of the	year			

SPONSORED RESEARCH

Share Price € 20.80
*Share price at the close of 02 May 2022

MAKS.MC/	
Market Cap	€ 162 m
Enterprise Value	€ 188 m
Free Float	€ 37 m
Nº Shares	8 m
Average Daily Volume	€ 10 k

Penormance	1111	3111	12111
Absolute %	5.1	-11.1	-26.2
Relative %	5.6	-10.0	-26.6
35.0	7		
30.0	M	- A	
25.0	7 4	الرم به	•
20.0			W
15.0			
10.0			
5.0			
0.0			
otho dato deto deto doto tho the oth	1 0472 0672 0	121 10121 12121	02/22 04/22

Madx

Making Science

Analyst Fernando Abril-Martorell +34 91 550 87 19 fabrilmartorell@alantraequities.com

ALANTRA Equities

KEY DATA															
P&L account (€ m)	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Cash flow (€ m)	FY18	FY19	FY20	FY21	FY22E	FY23E	FY2
Revenue	18.8	34.6	57.7	110.4	206.5	249.1	290.4	Net profit	(2.4)	0.7	1.5	(3.5)	2.2	4.3	6
cogs	(9.8)	(26.1)	(42.9)	(80.4)	(157.3)	(188.5)	(219.0)	Depreciation	0.1	0.4	0.9	3.8	4.8	5.4	5
Gross margin	9.0	8.4	14.8	30.0	49.3	60.5	71.4	Minorities		-	-	0.3	0.5	0.6	0
Opex	(7.5)	(7.1)	(11.3)	(27.7)	(39.7)	(47.6)	(55.5)	Non-cash adjustments	2.8	0.1	0.7	(6.1)	0.0	(0.0)	0
EBITDA	1.5	1.4	3.5	2.4	9.6	12.9	15.9	Total cash-flow (CF)	0.5	1.2	3.1	(5.5)	7.5	10.3	13.
One-offs	0.1	1.0	0.2	3.4	0.5	0.3	0.1	Capex	(0.4)	(8.0)	(1.2)	(2.5)	(3.2)	(3.3)	(3.3
Adj. EBITDA	1.6	2.4	3.7	5.7	10.1	13.1	16.0	Working capital investment	1.3	0.7	0.5	5.8	1.0	0.1	0.
D&A	(0.1)	(0.4)	(0.9)	(3.8)	(4.8)	(5.4)	(5.9)	Operating FCF	1.5	1.1	2.4	(2.2)	5.3	7.2	10.
Provisions & Other	(3.5)	(0.0)	-	(0.0)	-	-	-	Financial investments	-	-	-	-	-	-	
EBIT	(2.1)	0.9	2.6	(1.5)	4.8	7.4	10.0	Disposals (acquisitions)	-	(0.7)	(5.0)	(26.9)	(7.8)	(1.0)	(1.0
Net financials	(0.1)	0.0	0.0	0.0	(1.4)	(1.3)	(1.1)	Other	-	-	-	-	-	-	
Equity method & other	-	(0.1)	(0.5)	(1.1)	-	-	-	Dividends to minorities	-	-	-	-	-	-	
EBT	(2.2)	0.8	2.1	(2.5)	3.4	6.1	8.9	Rights issues	-	-	1.2	8.6	2.5	-	
Income tax expense	(0.2)	(0.1)	(0.5)	(0.7)	(0.7)	(1.2)	(1.8)	Free-cash-flow (FCF)	1.5	0.4	(1.5)	(20.5)	(0.0)	6.2	9.
Minorities	-	-	-	(0.3)	(0.5)	(0.6)	(0.7)	Dividends paid	-	-	-	-	-	-	
Net profit, reported	(2.4)	0.7	1.5	(3.5)	2.2	4.3	6.5	Share buybacks	-	-	-	-	-	-	
Adjustments	3.6	1.2	1.2	7.0	3.4	3.5	3.6	FCF after buy backs	1.5	0.4	(1.5)	(20.5)	(0.0)	6.2	9.
Net profit adjusted	1.2	1.8	2.7	3.5	5.6	7.8	10.1								
								Balance sheet (€ m)	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24
Nº of shares (m)	4.0	6.7	7.1	7.8	7.9	7.9	7.9	Shareholders equity	1	0	3	11	15	19	2
Nº of shares adjusted (m)	4.0	6.4	6.8	7.6	7.7	7.7	7.7	Minorities	-	-	-	1	5	5	
Treasury stock (m)	-	0.3	0.3	0.2	0.2	0.2	0.2	Provisions & others	3	2	5	5	5	5	
								Net debt (cash)	2	1	3	23	23	17	
YoY Growth	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Capital invested	5	4	10	40	49	47	4
Sales	40%	83%	67%	92%	87%	21%	17%								
EBITDA	36%	(9%)	153%	(32%)	n.m.	35%	24%	Other intangible	3	5	11	40	49	48	4
Adj. EBITDA	46%	49%	54%	55%	76%	30%	22%	PP&E	0	0	0	1	1	1	
EBIT	(290%)	(142%)	193%	(158%)	n.m.	56%	35%	Financial assets	0	0	0	1	1	1	
Net profit	n.m.	(128%)	132%	n.m.	(162%)	99%	51%	Equity method	3	0	0	0	0	0	(
								Working capital	(1)	(2)	(1)	(2)	(3)	(3)	(3
Sales by division	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Capital employed	5	4	10	40	49	47	4
Core Business	100%	100%	100%	94%	92%	91%	91%	Working capital/sales	(6.4%)	(5.5%)	(2.1%)	(1.4%)	(1.2%)	(1.1%)	(1.1%
E-commerce	0%	0%	0%	6%	8%	9%	9%								
								Financial ratios	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24
EBITDA by division	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Net debt/EBITDA	1.1X	0.9X	0.8X	9.9X	2.4X	1.3X	0.5
Core Business	100%	100%	100%	124%	107%	100%	96%	Net debt/Adj. EBITDA	1.0X	0.5X	0.7X	4.1X	2.3X	1.3X	0.5
E-commerce	0%	0%	0%	(24%)	(7%)	0%	4%	Gearing	222%	283%	95%	222%	154%	88%	30%
								Interest cover	(26.3X)	(301.2X)	(181.7X)	199.1X	3.4X	5.7X	9.1
Per share data	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E								
EPS	(0.60)	0.10	0.22	(0.45)	0.27	0.55	0.82	Margins & ratios	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24
EPS adjusted	0.29	0.28	0.39	0.45	0.70	0.99	1.28	EBITDA margin	8%	4%	6%	2%	5%	5%	59
CFPS	0.12	0.18	0.44	(0.71)	0.95	1.31	1.65	Effective tax rate	11%	(14%)	(26%)	26%	(20%)	(20%)	(20%
FCFPS	0.36	0.16	0.34	(0.28)	0.68	0.91	1.31	Pay-out	0%	0%	0%	0%	0%	0%	09
BVPS	0.19	0.07	0.41	1.35	1.92	2.46	3.28	ROCE (EBIT/CE)	(40%)	23%	25%	(4%)	10%	16%	229
DPS							_	ROE	n.a.	151%	54%	n.a.	14%	22%	259

03 May 2022 2

DISCLAIMER

ALANTRA Equities

Alantra Equities: This report (the "Report") has been prepared by Alantra Equities Sociedad de Valores, S.A. ("Alantra Equities"), a company pertaining to the Alantra Group that provides investment banking, asset management, equities brokerage, capital markets and financial advisory services. The date and hour of preparation of this investment recommendation refers to the date and hour of preparation and disclosure indicated on the first page of the Report.

Alantra Equities Sociedad de Valores, S.A. is a Spanish investment firm located in Madrid, calle José Ortega y Gasset 29, registered at the Comisión Nacional del Mercado de Valores (CNMV) with number 245.

Analyst certification: Each research analyst primarily responsible for the content of this research Report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this Report: (i) all the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, and (ii) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that research analyst in this research Report.

Important disclosures:

Alantra Equities receives remuneration from the issuer that this Report refers to in consideration of the research services that Alantra Equities provides to it. Therefore, this Report is considered sponsored research or marketing material for the purposes of the provisions of the Markets in Financial Instruments Directive.

Within the last 12 months, Alantra Equities and any other company pertaining to the Alantra Group is participating as co-global coordinator and co-bookrunner in connection with the capital increase of Making Science Group S.A.

This Report is solely for the information of clients of Alantra Equities and for distribution only under such circumstances as may be permitted by applicable law. Alantra Equities specifically prohibits the redistribution of this material in whole or in part without the prior written permission of Alantra Equities and therefore Alantra Equities accepts no liability whatsoever for the actions or third parties in this respect.

The opinions contained in this report and in other media used by Alantra Equities (such as the internet), reflect the opinion of the respective Analyst on the date of publication of such material and, therefore, may be subject to change at any time and without notice.

Nothing in this Report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. This Report is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor it is intended to be a complete statement or summary of the securities or markets referred to in this Report. Alantra Equities does not undertake that investors will obtain profits nor accept any liability for any investment losses arising from any use of this Report or its contents. Investments involve risks and investors should exercise prudence in making their investment decisions. This Report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this Report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas of the Alantra Group as a result of using different assumptions and criteria. Research will be initiated, updated and coverage ceased solely at the discretion of Alantra Equities. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Alantra Equities is under no obligation to keep current the information contained in this Report.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this Report.

Any prices stated in this Report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices.

Neither Alantra Equities nor any of the companies pertaining to the Alantra Group nor any of their shareholders, directors, employees or agents accept any liability for any loss or damage arising out of the use of all or any part of this Report.

Except as otherwise specified herein, this material is communicated by Alantra Equities to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to retail clients.

Important disclosures on conflicts of interest:

The analysts responsible for the preparation of this Report may interact with trading desk personnel, sales personnel and investment managers. Alantra Equities belongs to the Alantra Group, a group that is engaged in financial advisory services, asset management as well as securities trading and brokerage, and capital markets. Alantra Equities, any other company pertaining to the Alantra Group, and any of their shareholders, directors, employees may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments directly or indirectly the subject of this publication. The Alantra Group relies on information barriers to control the flow of information contained in one or more areas within the Alantra Group, into other areas, units, groups or affiliates of the Alantra Group. The Alantra Group may do and seek to do business with companies covered in its research reports. As a result, investors should be aware that the Alantra Group may have a conflict of interest.

For the purposes of mitigating any conflict of interests, the Alantra Group has established, implemented and maintains an effective conflicts of interest policy appropriate to its size and organisation and to the nature, scale and complexity of its business. The policy, periodically revised, can be consulted at the Alantra Equities website through the following link: Conflicts of Interest. Investors should consider this Report as only a single factor in making their investment decisions.

In addition, Alantra Group's website (www.alantra.com) provides information on closed and public corporate transactions, not subject to confidentiality, in which the Alantra Group, through its subsidiaries in the investment banking area, has acted as financial advisor, from time to time.

03 May 2022 3

DISCLAIMER

The disclosures contained in research Report produced by Alantra Equities shall be governed by and construed in accordance with Spanish law.

The receipt of this Report implies full acceptance by its recipients of the contents of this disclaimer.

03 May 2022 4